文献速递炎症性肠病

1000例炎症性肠病患者停用抗TNF治疗后的长期临床结局:EVODIS长期研究

Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study.
PubMed 文献 · Aliment Pharmacol Ther · 2021-05-07

EVODIS长期研究为观察性、回顾性、多中心研究,纳入1055例达到临床缓解后停用抗TNF的炎症性肠病患者,中位随访34个月。停药后复发率为每患者年12%(95%CI=11-14),累积复发率50%(95%CI=47-53),1年19%、2年31%、3年38%、4年44%、5年48%。复发后60%患者重新使用同一抗TNF,其中73%重获缓解。

要点

  • 停用抗TNF后每患者年复发率为12%,5年累积复发率48%
  • 复发后重新使用同一抗TNF,73%患者可重获缓解
  • 重新治疗无效者中48%可通过其他治疗达到缓解

核心结论

  • 相当比例停用抗TNF的炎症性肠病患者维持缓解,但长期复发风险持续存在。
  • 复发后重新使用同一抗TNF通常有效,无效者可换用其他治疗。

研究设计与样本

  • 观察性、回顾性、多中心研究,为EVODIS研究的长期扩展。
  • 共纳入1055例达到临床缓解后停用抗TNF的克罗恩病或溃疡性结肠炎患者。
  • 中位随访时间34个月。

主要发现

  • 复发率为每患者年12%(95%CI=11-14)。
  • 累积复发率为50%(95%CI=47-53):随访1年19%、2年31%、3年38%、4年44%、5年48%。
  • 复发后60%患者重新使用同一抗TNF,其中73%重获缓解。
  • 重新治疗未应答的75例患者中,48%通过其他治疗达到缓解。
  • 复发后启动其他治疗的190例患者中,62%通过新治疗达到缓解。

关键数值与推荐

  • 临床缓解定义:克罗恩病Harvey-Bradshaw指数≤4分;溃疡性结肠炎部分Mayo评分≤2分;肛周病变在轻柔指压无瘘管引流。

临床怎么用

  • 停用抗TNF后需长期监测复发,尤其随访前5年。
  • 复发时重新使用同一抗TNF是有效策略。
  • 重新治疗无效者可考虑其他治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The long-term outcome of patients after antitumour necrosis factor alpha (anti-TNF) discontinuation is not well known. AIMS: To assess the risk of relapse in the long-term after anti-TNF discontinuation. METHODS: This was an extension of the evolution after anti-TNF discontinuation in patients with inflammatory bowel disease (EVODIS) study (Crohn's disease or ulcerative colitis patients treated with anti-TNFs in whom these drugs were withdrawn after achieving clinical remission) based in the same cohort of patients whose outcome was updated. Clinical remission was defined as a Harvey-Bradshaw index ≤4 points in Crohn's disease, a partial Mayo score ≤2 in ulcerative colitis and the absence of fistula drainage despite gentle finger compression in perianal disease. RESULTS: This was an observational, retrospective, multicenter study. A total of 1055 patients were included. The median follow-up time was 34 months. The incidence rate of relapse was 12% per patient-year (95% confidence interval [CI] = 11-14). The cumulative incidence of relapse was 50% (95% CI = 47-53): 19% at one year, 31% at 2 years, 38% at 3 years, 44% at 4 years and 48% at 5 years of follow-up. Of the 60% patients retreated with the same anti-TNF after relapse, 73% regained remission. Of the 75 patients who did not respond, 48% achieved remission with other therapies. Of the 190 patients who started other therapies after relapse, 62% achieved remission with the new treatment. CONCLUSIONS: A significant proportion of patients who discontinued the anti-TNF remained in remission. In case of relapse, retreatment with the same anti-TNF was usually effective. Approximately half of the patients who did not respond after retreatment achieved remission with other therapies.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Casanova MJ, Chaparro M, Nantes Ó, et al. Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study. Aliment Pharmacol Ther. 2021. PMID: 33962482. doi:10.1111/apt.16361

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。